Literature DB >> 11385015

Visual field loss associated with vigabatrin: pathological correlations.

J Ravindran1, P Blumbergs, J Crompton, G Pietris, H Waddy.   

Abstract

Pathological changes are reported in the anterior visual pathways of a 41 year old man with complex partial seizures treated with vigabatrin who developed bilateral visual field constriction. There was peripheral retinal atrophy with loss of ganglion cells and loss of nerve fibres in the optic nerves, chiasm, and tracts. No evidence of intramyelinic oedema was seen. These findings suggest that the primary site of injury lies within the ganglion cells in the retina. The degree of atrophy seen would suggest that the visual field loss is irreversible.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385015      PMCID: PMC1737373          DOI: 10.1136/jnnp.70.6.787

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.

Authors:  John M Wild; David L Fone; Saleh Aljarudi; Charlotte Lawthom; Philip E M Smith; Robert G Newcombe; Gareth D Lewis
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

2.  Evaluating risks for vigabatrin treatment.

Authors:  Gregory L Krauss
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

3.  Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.

Authors:  Betül Tuğcu; Mesrure Köseoğlu Bitnel; Fatma Selin Kaya; Betül Tekin Güveli; Dilek Ataklı
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.307

4.  Vigabatrin induced Cell loss in the Cerebellar Cortex of Albino Rats.

Authors:  Deepa Singh; Sunder Lal Jethani; Aksh Dubey
Journal:  J Clin Diagn Res       Date:  2013-11-10

5.  The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin.

Authors:  John M Wild; Saleh Aljarudi; Philip E M Smith; Carlo Knupp
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

6.  A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.

Authors:  G L Krauss; M A Johnson; S Sheth; N R Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

7.  Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats.

Authors:  Firas Jammoul; Julie Dégardin; Dorothée Pain; Pauline Gondouin; Manuel Simonutti; Elisabeth Dubus; Romain Caplette; Stéphane Fouquet; Cheryl M Craft; José A Sahel; Serge Picaud
Journal:  Mol Cell Neurosci       Date:  2010-02-01       Impact factor: 4.314

8.  Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.

Authors:  Vesna Ponjavic; Lotta Gränse; Sten Kjellström; Sten Andréasson; Anitha Bruun
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

9.  Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

Authors:  J Raymond Buncic; Carol A Westall; Carole M Panton; J Robert Munn; Leslie D MacKeen; William J Logan
Journal:  Ophthalmology       Date:  2004-10       Impact factor: 12.079

10.  Taurine deficiency damages retinal neurones: cone photoreceptors and retinal ganglion cells.

Authors:  David Gaucher; Emilie Arnault; Zoé Husson; Nicolas Froger; Elisabeth Dubus; Pauline Gondouin; Diane Dherbécourt; Julie Degardin; Manuel Simonutti; Stéphane Fouquet; M A Benahmed; K Elbayed; Izzie-Jacques Namer; Pascale Massin; José-Alain Sahel; Serge Picaud
Journal:  Amino Acids       Date:  2012-04-04       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.